BioSpace News Archive

Antibe Therapeutics Inc., a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update.

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced clinical and program updates demonstrating expansion and advancement of its mRNA pipeline.

Curevo Vaccine, a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, announced Dr. Guy De La Rosa has joined the company as its new Chief Medical Officer.

BridgeBio Pharma, Inc. today announced that on April 7, 2023, the compensation committee of BridgeBio’s board of directors granted 11 new employees restricted stock units for an aggregate of 134,300 shares of the Company’s common stock.

Atsena Therapeutics today announced that 6-month safety and efficacy data from the ongoing Phase I/II clinical trial of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1) will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting.

DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a digital health AI company, is pleased to announce that effective April 11, 2023, the Company is listed on the OTCQB Venture Market (“OTCQB”) under the symbol “DGNMF”.

Mosaic ImmunoEngineering, Inc. today announced that the US Patent and Trademark Office (USPTO) has issued an additional patentto protect the technology behind Mosaic’s lead immuno-oncology product candidate, MIE-101.

Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced it has completed enrollment of a Phase 3 trial in hemodialysis access.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, announced three presentations at the upcoming 2023 American Academy of Neurology Annual Meeting, taking place April 22-27, 2023, in Boston, MA.

IN8bio, Inc. (Nasdaq: INAB) today announced that new data from the ongoing Phase 1 trial evaluating INB-100, an allogeneic, gamma-delta T cell therapy, in patients with hematologic malignancies undergoing haploidentical stem cell transplantation (HSCT), will be presented at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), being held in Paris, France April 23-26.